167 related articles for article (PubMed ID: 21667624)
1. FDA approvals of old drugs put new pressure on payers.
Silverman E
Manag Care; 2011 May; 20(5):30-1. PubMed ID: 21667624
[No Abstract] [Full Text] [Related]
2. Paying for drug approvals--who's using whom?
Avorn J
N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
[No Abstract] [Full Text] [Related]
3. FDA proposes higher fees for drug approvals to cover postmarketing surveillance.
Tanne JH
BMJ; 2007 Jan; 334(7586):177. PubMed ID: 17255596
[No Abstract] [Full Text] [Related]
4. Controversy still swirls around FDA user fees: since 1992, the prescription drug user fee act and reauthorizations have sped up new drug approvals--but does speed equal safety?
Ullman K
Ann Neurol; 2013 Nov; 74(5):A10-1. PubMed ID: 24353218
[No Abstract] [Full Text] [Related]
5. Therapeutics, drug pricing and innovation.
Somberg J
Am J Ther; 2003; 10(6):381. PubMed ID: 14624273
[No Abstract] [Full Text] [Related]
6. Rx: Canadian drugs.
Zuger A
N Engl J Med; 2003 Dec; 349(23):2188-90. PubMed ID: 14657425
[No Abstract] [Full Text] [Related]
7. Drug safety reform at the FDA--pendulum swing or systematic improvement?
McClellan M
N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
[No Abstract] [Full Text] [Related]
8. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
9. Assuring the benefits of modern medicine for all Americans.
Woodcock J
Healthplan; 2003; 44(5):23-6. PubMed ID: 14556608
[No Abstract] [Full Text] [Related]
10. What ails the FDA?
Okie S
N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
[No Abstract] [Full Text] [Related]
11. 'New' FDA delivers in 2003.
Schmidt E; Wong R
Nat Rev Drug Discov; 2003 Dec; 2(12):941-2. PubMed ID: 14756139
[No Abstract] [Full Text] [Related]
12. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
13. New law to improve animal drug review.
FDA Consum; 2004; 38(1):5. PubMed ID: 15032189
[No Abstract] [Full Text] [Related]
14. Beware the increasing cost and number of orphan drugs.
Silverman E
Manag Care; 2013 Mar; 22(3):10-4. PubMed ID: 23610800
[No Abstract] [Full Text] [Related]
15. Drug development for neglected diseases - the trouble with FDA review vouchers.
Kesselheim AS
N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
[No Abstract] [Full Text] [Related]
16. America's other drug problem: how the drug industry distorts medicine and politics.
Relman AS; Angell M
New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
[No Abstract] [Full Text] [Related]
17. User fees to hasten FDA review.
Gershon D
Nature; 1992 Oct; 359(6396):567. PubMed ID: 1406982
[No Abstract] [Full Text] [Related]
18. FDA joins market.
Gershon D
Nature; 1993 Jul; 364(6433):93. PubMed ID: 8321293
[No Abstract] [Full Text] [Related]
19. Shifting gears.
Tweed V
Bus Health; 1994 May; 12(5):28-9, 32, 34 passim. PubMed ID: 10134334
[No Abstract] [Full Text] [Related]
20. PDUFA reauthorization--drug safety's golden moment of opportunity?
Hennessy S; Strom BL
N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
[No Abstract] [Full Text] [Related]
[Next] [New Search]
